drugset / Trial / NCT04450901
Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1/2a, open-label, multicenter, dose-escalation/dose-expansion study of YBL-006, in participants with Advanced Solid Tumors. This multicenter study will be conducted in approximately 11-14 participants in the dose escalation phase, and approximately 39-76 participants in dose expansion phase.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YBL-006 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | YBL-006 | Unknown | 2 mg/kg | Intravenous |
| Subject | YBL-006 | Unknown | 5 mg/kg | Intravenous |
| Subject | YBL-006 | Unknown | 10 mg/kg | Intravenous |
| Subject | YBL-006 | Unknown | 200 mg | Intravenous |
| Subject | YBL-006 | Unknown | 300 mg | Intravenous |